RCKT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
46.9M
-3.3%
48.5M
+10.3%
44.0M
-15.9%
52.2M
-26.6%
71.1M
R&D
29.5M
-6.2%
31.5M
+7.2%
29.3M
-13.9%
34.1M
-20.1%
42.7M
SG&A
17.4M
+2.2%
17.1M
+16.2%
14.7M
-20.0%
18.4M
-26.7%
25.0M
Operating Income
-46922000
+3.3%
-48511000
-10.3%
-43963000
+15.9%
-52247000
+26.6%
-71149000
EBITDA
-45358000
+3.3%
-46903000
-10.7%
-42353000
+14.8%
-49717000
+24.3%
-65638000
Net Income
123.2M
+352.4%
-48823000
-14.8%
-42538000
+15.5%
-50332000
+27.0%
-68919000
EPS (Basic)
$1.09
+359.5%
$-0.42
-10.5%
$-0.38
+15.6%
$-0.45
+27.4%
$-0.62
EPS (Diluted)
$1.08
+357.1%
$-0.42
-10.5%
$-0.38
+15.6%
$-0.45
+27.4%
$-0.62
Shares (Diluted)
114.5M
+2.1%
112.1M
+0.3%
111.8M
+0.2%
111.6M
+0.5%
111.0M
Rocket Pharmaceuticals (RCKT) โ€” Financials